HedgeChatter

  • Home /
  • Tag Archives

ICPT

INTERCEPT 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. – ICPT

[Marketwired] – Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until April 22, 2014 to file … moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click […]

April 19, 2014 Bystocknews , Comments Off on INTERCEPT 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. – ICPT read more

Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session

[GlobeNewswire] – -Notable Improvements on Key Endpoints as Early as Two Weeks After OCA Treatment Initiation moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click here to view […]

April 12, 2014 Bystocknews , Comments Off on Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session read more

Intercept’s liver disease drug proves highly effective in study

[Reuters – UK Focus] – A drug being developed by Intercept Pharmaceuticals Inc led to significant improvement in signs of a rare liver disease that primarily affects middle-aged women, likely reducing the risk of need for liver transplant and of death, a moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who […]

April 12, 2014 Bystocknews , Comments Off on Intercept’s liver disease drug proves highly effective in study read more

Data From Intercept’s Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014

[GlobeNewswire] – NEW YORK — Intercept Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced … moreView todays social media effects on ICPTView the latest stocks trending across Twitter. Click to view dashboardSee who Intercept is hiring next, click here to view […]

April 4, 2014 Bystocknews , Comments Off on Data From Intercept’s Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014 read more